ATRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Adhera Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Adhera Therapeutics's Piotroski F-Score or its related term are showing as below:
The historical data trend for Adhera Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adhera Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 4.00 | 5.00 | 3.00 | 3.00 | 3.00 |
Adhera Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Piotroski F-Score | Get a 7-Day Free Trial | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 |
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep23) TTM: | Last Year (Sep22) TTM: |
Net Income was -0.335 + -0.886 + 0.271 + -3.536 = $-4.49 Mil. Cash Flow from Operations was -0.059 + -0.31 + -0.316 + -0.029 = $-0.71 Mil. Revenue was 0 + 0 + 0 + 0 = $0.00 Mil. Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil. Average Total Assets from the begining of this year (Sep22) to the end of this year (Sep23) was (0.256 + 0.079 + 0.104 + 0.082 + 0.044) / 5 = $0.113 Mil. Total Assets at the begining of this year (Sep22) was $0.26 Mil. Long-Term Debt & Capital Lease Obligation was $0.00 Mil. Total Current Assets was $0.04 Mil. Total Current Liabilities was $26.36 Mil. |
Net Income was -1.669 + -0.074 + 0.099 + -1.803 = $-3.45 Mil. Revenue was 0 + 0 + 0 + 0 = $0.00 Mil. Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil. Average Total Assets from the begining of last year (Sep21) to the end of last year (Sep22) was (0.151 + 0.196 + 0.17 + 0.976 + 0.256) / 5 = $0.3498 Mil. Total Assets at the begining of last year (Sep21) was $0.15 Mil. Long-Term Debt & Capital Lease Obligation was $0.00 Mil. Total Current Assets was $0.26 Mil. Total Current Liabilities was $22.06 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Adhera Therapeutics's current Net Income (TTM) was -4.49.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Adhera Therapeutics's current Cash Flow from Operations (TTM) was -0.71.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Sep22) |
= | -4.486 | / | 0.256 | |
= | -17.5234375 |
ROA (Last Year) | = | Net Income | / | Total Assets (Sep21) |
= | -3.447 | / | 0.151 | |
= | -22.82781457 |
Adhera Therapeutics's return on assets of this year was -17.5234375. Adhera Therapeutics's return on assets of last year was -22.82781457.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Adhera Therapeutics's current Net Income (TTM) was -4.49. Adhera Therapeutics's current Cash Flow from Operations (TTM) was -0.71.
==> -0.71 > -4.49 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Sep23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep22 to Sep23 |
= | 0 | / | 0.113 | |
= | 0 |
Gearing (Last Year: Sep22) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep21 to Sep22 |
= | 0 | / | 0.3498 | |
= | 0 |
Adhera Therapeutics's gearing of this year was 0. Adhera Therapeutics's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Sep23) | = | Total Current Assets | / | Total Current Liabilities |
= | 0.044 | / | 26.36 | |
= | 0.0016692 |
Current Ratio (Last Year: Sep22) | = | Total Current Assets | / | Total Current Liabilities |
= | 0.256 | / | 22.063 | |
= | 0.01160314 |
Adhera Therapeutics's current ratio of this year was 0.0016692. Adhera Therapeutics's current ratio of last year was 0.01160314.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Adhera Therapeutics's number of shares in issue this year was 4.304. Adhera Therapeutics's number of shares in issue last year was 3.161.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 0 | / | 0 | |
= |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 0 | / | 0 | |
= |
Adhera Therapeutics's gross margin of this year was . Adhera Therapeutics's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Sep22) |
= | 0 | / | 0.256 | |
= | 0 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Sep21) |
= | 0 | / | 0.151 | |
= | 0 |
Adhera Therapeutics's asset turnover of this year was 0. Adhera Therapeutics's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 1 | + | 1 | + | 1 | + | 0 | + | 0 | + | 0 | + | 0 | |
= | 3 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Adhera Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Adhera Therapeutics (OTCPK:ATRX) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Adhera Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Zahed Subhan | director | 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820 |
Trond Kydd Waerness | director | 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820 |
Rice Charles L Jr | director | C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
Andrew Albert Kucharchuk | director, officer: Chief Executive Officer | 549 MILGATE PLACE, BATON ROUGE LA 70810 |
Rhonda L. Stanley | officer: SVP Finance & Accounting | 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703 |
Nancy R. Phelan | director | 812 MAPLEWOOD ROAD, WAYNE PA 19087 |
Robert Eric Teague | officer: Chief Financial Officer | C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703 |
Uli Hacksell | director | 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121 |
Robert Jr. Moscato | officer: CEO | 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Timothy Boris | director | 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Peter D. Weinstein | officer: Chief Legal Officer | C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748 |
Amit B. Shah | officer: Chief Financial Officer | 10 AGUILA, ALISO VIEJO CA 92656 |
Erik C. Emerson | officer: Chief Commercial Officer | 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102 |
Mihir Munsif | officer: Chief Operating Officer | 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679 |
From GuruFocus
By [email protected] [email protected] • 09-06-2019
By Marketwired Marketwired • 06-20-2018
By GuruFocusNews GuruFocusNews • 05-29-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By Marketwired Marketwired • 09-24-2018
By gurufocus • 07-30-2009
By ACCESSWIRE AccessWire • 04-12-2019
By gurufocus • 05-15-2009
By gurufocus 10qk • 05-17-2010
By Marketwired Marketwired • 06-29-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.